Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Sees Significant Growth in Short Interest

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) saw a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling 23,900 shares, a growth of 119.3% from the February 29th total of 10,900 shares. Currently, 2.8% of the company’s shares are sold short. Based on an average trading volume of 23,500 shares, the days-to-cover ratio is currently 1.0 days.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of VRPX. Renaissance Technologies LLC acquired a new stake in Virpax Pharmaceuticals in the 1st quarter valued at approximately $348,000. Vanguard Group Inc. increased its position in shares of Virpax Pharmaceuticals by 8.5% during the 3rd quarter. Vanguard Group Inc. now owns 370,884 shares of the company’s stock valued at $441,000 after purchasing an additional 28,907 shares during the period. Finally, Citigroup Inc. acquired a new position in shares of Virpax Pharmaceuticals during the 1st quarter valued at $27,000. Hedge funds and other institutional investors own 32.23% of the company’s stock.

Virpax Pharmaceuticals Stock Performance

VRPX stock opened at $3.77 on Thursday. Virpax Pharmaceuticals has a 1 year low of $2.40 and a 1 year high of $11.77. The firm has a market cap of $4.41 million, a P/E ratio of -0.32 and a beta of 1.30. The stock has a 50-day simple moving average of $3.60 and a 200-day simple moving average of $5.06.

Virpax Pharmaceuticals Company Profile

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.